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Aims. To evaluate whether reduced waiting time influences survival of patients treated with whole-brain radiotherapy (WBRT) for
brain metastases.Materials andMethods. Retrospective intention-to-treat study including 110 patients treated with primaryWBRT
(typically 10 fractions of 3Gy; no other treatment between diagnosis and WBRT). Uni- and multivariate tests were performed.
Results. Median delay between imaging diagnosis and WBRT was 12 days (range 0–66 days). WBRT started within 1 week in 36%,
during the second week in 28%, and during the third week in 18% of patients. No significant correlation between waiting time
and survival was evident, except for one subgroup of patients. Those without extracranial metastases (potentially more threatened
by worse intracranial disease control) survived for a median of 2.5 months from WBRT if waiting time was 2 weeks or longer
as compared to 5.6 months if waiting time was shorter than 2 weeks (𝑃 = 0.03). The same correlation was seen if survival was
computed from imaging diagnosis. Conclusion. If departmental resources are not sufficient to provide immediate WBRT within 2
weeks to all patients, those without extracranial metastases should be prioritised. This study did not address the impact of waiting
time on quality of life or symptom palliation.
1. Introduction
On an international scale, access to palliative radiother-
apy varies with geographic region, health care system, and
sociodemographic factors [1, 2]. The presence of waiting
lists might cause distress, unnecessary symptom burden, and
under certain circumstances compromised outcomes, at least
if long waiting time is unavoidable. Regarding treatment of
brain metastases, a considerable number of patients continue
to receive palliative whole-brain radiotherapy (WBRT) [3,
4]. Administration of 10 fractions of 3Gy over 2 weeks
or 5 fractions of 4Gy over one week is commonly used
fractionation regimens in many countries [5]. Given that
median survival of patients managed with best supportive
care is limited (in the order of 4–6 weeks [6, 7]), one might
assume that delays in starting WBRT should be minimised,
if such treatment is indicated and the preferred therapeutic
option. Clinical data on the impact of variable waiting times
between imaging diagnosis of brain metastases and initiation
of WBRT on survival after radiotherapy are scarce [8].
Therefore, we evaluated survival of a contemporary cohort of
patients treated with WBRT.
2. Patients and Methods
We analysed patients from a previously described multi-
institutional brain metastases database, which is maintained
and updated by the first author [7, 9]. The patients were
treated at Nordland Hospital (Bodø) and University Hos-
pital of Northern Norway (Tromsø). For this retrospective
intention-to-treat study, all patients treated with primary
WBRT (prescribed dose 10 fractions of 3Gy or 5 fractions
of 4Gy; no previous surgery or radiosurgery; no radiation
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Table 1: Patient characteristics (𝑛 = 110): no significant difference in age, KPS, number of brain metastases, extracranial metastases, primary
tumour control, DS-GPA and RPA classification, radiation dose, and time interval (𝑃 = 0.22 or more); significant difference: primary disease
type (𝑃 = 0.03).
Parameter Interval < 12 days Interval ≥ 12 days
Median age, years 64 64
Median KPS 60 70
Median DS-GPA score (min. 0, max. 4 points) 1.0 1.0
Number of BM: 1 (%) 5 9
Number of BM: 2-3 (%) 17 16
Number of BM: >3 (%) 25 27
Extracranial metastases (%) 43 38
No extracranial metastases (%) 5 15
Uncontrolled primary tumour (%) 16 25
Controlled primary tumour (%) 31 28
DS-GPA class I versus II versus III versus IV (%) 2, 4, 9, 33 1, 5, 17, 30
RPA class I versus II versus III (%) 2, 20, 25 3, 26, 24
NSCLC, SCLC (%) 15, 8 32, 2
Breast, MM, and GI (%) 9, 3, 6 3, 4, 6
Kidney, others (%) 4, 2 4, 3
Total dose 20Gy (%) 12 17
Total dose 30Gy (%) 35 35
Simultaneous detection of BM and primary tumour (%) 8 17
Time interval to BM 1–12 months (%) 23 17
Time interval to BM 13–36 months (%) 7 9
Time interval to BM > 36 months (%) 9 8
KPS: Karnofsky performance status; BM: brain metastases; DS-GPA: diagnosis-specific graded prognostic assessment; NSCLC: nonsmall cell lung cancer;
SCLC: small cell lung cancer; MM: malignant melanoma; GI: gastrointestinal primary tumour.
Table 2: Median survival after whole-brain radiotherapy (WBRT).




Interval < 12 days 2.6 months 2.8 months
Interval ≥ 12 days 2.5 months 3.3 months
Start within 1 week 2.3 months 2.4 months
Start during week 2 2.2 months 2.6 months
Start during week 3 2.7 months 3.3 months
Start after > 3 weeks 2.8 months 4.2 months
boost) between 2005 and 2012 were selected (𝑛 = 110).
All patients who failed to complete WBRT are included in
the analysis. The choice of WBRT dose was made by the
treating physician taking into account the life expectancy of
individual patients. WBRT commenced without preceding
systemic therapy after imaging diagnosis of brain metastases.
The patient characteristics are shown in Table 1. For com-
parison of dichotomous variables the Chi-Square Test and
Fisher’s Exact Test, where applicable, were employed and for
continuous variables the Mann-Whitney 𝑈 Test (always 2-
sided). Actuarial survival was calculated with the Kaplan-
Meier method and compared between different groups with
the log-rank test. Thirteen patients (12%) were alive at date
of the last followup (November 01, 2012) and thus censored.
Their median followup was 5 months (range 1–59 months).
The prognostic impact of baseline parameters and waiting
time was first tested in univariate analyses (log-rank test). For
multivariate analysis of survival Cox regression analysis was
used. Waiting time was entered as continuous or categorical
variable with different cutoff values. A 𝑃 value <0.05 was
considered statistically significant.
3. Results
Of all 110 patients included in the study 36 (33%) started
WBRT within one week from imaging diagnosis of brain
metastases. Another 28% (31 patients) started during the
second week and 18% (20 patients) during the third week.
Median delay was 12 days (range 0–66 days). Median survival
was 3.0 months from imaging diagnosis and 2.5 months
from the first dose of WBRT. As shown in Table 2, no
significant correlation between waiting time and survival
was evident. The small group of 16 patients (15%) with
waiting time >28 days had median survival comparable to
patients with waiting time ≤28 days (2.5 months fromWBRT,
𝑃 = 0.92, and 4.2 months from imaging diagnosis, 𝑃 =
0.46). Given that most but not all baseline characteristics
were balanced between the two groups with waiting time
<12 days versus ≥12 days (as shown in Table 1 significant
differences regarding primary tumour type were seen), a
series ofmultivariate Cox regression analyses was performed.
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Waiting time was entered as categorical variable (stratified
by median or 4 strata, i.e., <1 week, 1-2 weeks, 2-3 weeks,
or more) or as continuous variable. Primary tumour type
and prognostic scores (recursive partitioning analysis (RPA)
classification [10] and diagnosis-specific graded prognostic
assessment (DS-GPA) score [11]) were entered as covariates.
No significant correlation between waiting time and survival
fromWBRT or imaging diagnosis was identified (details not
shown).
In order to explore the hypothesis that specific subgroups
of patients could be more vulnerable to detrimental effects of
longer waiting time, more detailed analyses were performed.
Irrespective of cutoff chosen, Karnofsky performance status
(KPS) and age did not turn out to be relevant. However,
extracranial disease extent might be important. In patients
with extracranial metastases, survival depends on both intra-
and extracranial disease control and is typically shorter than
in patients without extracranial metastases (3.0 versus 4.2
months in the present study). In patients with brain metas-
tases only, intracranial disease control is more important, and
delayed WBRT could threaten survival. Twenty-one patients
in this study did not harbour extracranial metastases.Median
survival was 2.5 months from WBRT with waiting time ≥2
weeks and 5.6 months with shorter waiting time (𝑃 = 0.03).
Comparable results were seen for survival from imaging
diagnosis (3.8 versus 5.9 months, 𝑃 = 0.03).
The risk of being unable to complete the prescribed course
of WBRT was similar across all groups (9% each for interval
<12 days versus ≥12 days, 9% for start within one week, 11%
for start during the second week, 5% for start during the third
week, 10% for start after more than 3 weeks, and 𝑃 > 0.6 for
both statistical approaches).
Survival from imaging diagnosis was significantly longer
in patients with breast cancer (median 13.9 months) and
small cell lung cancer (median 5.3 months) than those with
other primary diagnoses. Both RPA classification and DS-
GPA score also predicted survival. Median was 29.9 months
in RPA class I, 4.2 months in class II, and 2.1 months in
class III (𝑃 = 0.0001). Median was not reached for DS-GPA
class I, 4.4 months for class II, 3.7 months for class III, and
2.3 months for class IV (𝑃 = 0.002). In the multivariate
analyses mentioned above only RPA and primary tumour
type remained statistically significant.
4. Discussion
Few if any patients with brain metastases would be willing
to participate in a randomised trial examining the impact
of different waiting times on outcomes after WBRT. In the
absence of such trials, the present retrospective intention-
to-treat analysis provides interesting results. As shown in
Table 2, the data do not suggest that moderately delayed
WBRT compromises survival for the majority of patients.
Whether or not other endpoints such as neurological func-
tion status, steroid dependency or patient reported quality of
life might be compromised is currently unknown and cannot
be examined retrospectively. Given that extended waiting
times are unlikely to provide any medical advantage, efforts
should be undertaken to minimise delay between diagnosis
and WBRT. Our data suggest that it might be justified to
prioritise patients without extracranial metastases in cases
where departmental waiting lists cannot be avoided, with the
reason being that untreated brain metastases might shorten
survival in patients who are not immediately threatened
by progression in extracranial sites. However, it must be
acknowledged that other parameters might also be impor-
tant. Such parameters might include neurological function,
symptomburden,mass effect, or intracranial tumour volume.
Due to a lack of recording in our database we were unable to
include any of them. Regarding further potential shortcom-
ings of this study, one should be aware of its retrospective
nature and the limited patient numbers.
Themajor reason for variable waiting times in the present
patient population was limited capacity at the treating insti-
tutions, but the magnitude of this problem was not constant
over time and impacted patients quite randomly. For each
given year, seasonal variations, machine maintenance, and
breakdown episodes occurred. Occasionally, delayed WBRT
was caused by unexpected intercurrent comorbid conditions
or patient request. Even during time periods with heavy
workload and longer waiting lists, doctors could influence to
some degree whether a given patient started WBRT rapidly
because a certain number of emergency slots existed. If
doctors are effective at distinguishing between more and
less aggressive disease states, the impact of waiting time
on outcomes might be diminished. These considerations
might also explain why some studies on delay of postoper-
ative radiotherapy for glioblastoma described a correlation
between longer waiting time and decreased survival while
others did not [12]. A combined analysis suggested that
moderate wait periods (up to 4–6 weeks) are safe [13], but
these data are difficult to comparewith ours (unresected brain
metastases).
In a previous study by Lutterbach et al. waiting time was
examined only for patients who underwent biopsy or resec-
tion before WBRT [8]. Median delay was 13 days, but time
from initial imaging diagnosis was not reported. Impact on
survival was not analysed either. In a recent randomised trial
of WBRT with or without motexafin gadolinium, the median
time from brain metastasis diagnosis to randomisation was
15 days [14]. Median interval to neurologic progression was
10 months (delay 2 weeks or less) versus 8.8 months (delay 2–
4 weeks) in theWBRT arm alone. Neither significance of this
difference nor survival outcomes for different magnitudes
of delay were reported. We were unable to identify more
reports focussing on impact of waiting time. Danjoux et
al. reported that initiation of a rapid response radiotherapy
program was effective in reducing waiting time for palliative
radiotherapy [15]. Impact of waiting time on survival was
not analysed in detail. Whether or not waiting time com-
promises outcome might depend on primary tumour type,
its biological behaviour, and related differences in growth
rate or doubling time. In patients with nonsmall cell lung
cancer waiting for stereotactic radiotherapy, only 23% of
tumours did not show volume increase during waiting times
>25 days [16]. In squamous cell head and neck cancer, 62%
of cases had measurable increase in tumour volume before
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radiotherapy,median 46% (median interval between imaging
studies 28 days) [17]. Other tumours might grow less rapidly.
However, for individual patients prediction is often difficult
if not impossible. Indirectly, longitudinal studies such as
those in lung and head and neck cancer, provide arguments
against waiting times in excess of 2-3 weeks. Regarding brain
metastases, there is a need to perform further analyses,
for example, based on published randomised studies that
included prospective documentation of endpoints other than
survival and larger groups of patients.
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